Astrazeneca Ab Company Profile

What is the competitive landscape for ASTRAZENECA AB

ASTRAZENECA AB has twelve approved drugs.

There are thirty-four US patents protecting ASTRAZENECA AB drugs. There is one tentative approval on ASTRAZENECA AB drugs.

There are nine hundred and fifteen patent family members on ASTRAZENECA AB drugs in fifty-four countries and one hundred and forty-nine supplementary protection certificates in twenty countries.

Summary for Astrazeneca Ab

International Patents:	915
US Patents:	34
Tradenames:	13
Ingredients:	10
NDAs:	12
Drug Master File Entries:	2
Patent Litigation for Astrazeneca Ab:	See patent lawsuits for Astrazeneca Ab
PTAB Cases with Astrazeneca Ab as patent owner:	See PTAB cases with Astrazeneca Ab as patent owner

Drugs and US Patents for Astrazeneca Ab

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	QTERNMET XR	dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210874-003	May 2, 2019		DISCN	Yes	No	9,616,028*PED				Y
Astrazeneca Ab	QTERN	dapagliflozin; saxagliptin hydrochloride	TABLET;ORAL	209091-001	Feb 27, 2017		DISCN	Yes	No	8,221,786*PED				Y
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014		DISCN	Yes	No	8,361,972*PED				Y
Astrazeneca Ab	QTERN	dapagliflozin; saxagliptin hydrochloride	TABLET;ORAL	209091-002	May 2, 2019		DISCN	Yes	No	8,716,251*PED				Y
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-001	Jan 8, 2014		RX	Yes	No	8,721,615*PED				Y

Expired US Patents for Astrazeneca Ab

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-002	Sep 25, 2007	5,686,411
Astrazeneca Ab	KOMBIGLYZE XR	metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200678-002	Nov 5, 2010	8,628,799
Astrazeneca Ab	ONGLYZA	saxagliptin hydrochloride	TABLET;ORAL	022350-002	Jul 31, 2009	6,395,767
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-001	Mar 16, 2005	6,114,304
Astrazeneca Ab	QTERNMET XR	dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210874-001	May 2, 2019	6,936,590

Paragraph IV (Patent) Challenges for ASTRAZENECA AB drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	250 mg/mL, 1.2 mL and 2.4 mL prefilled syringe		2014-06-11
	HydrochlorideExtended-release Tablets	2.5 mg/1000 mg		2018-10-29
	Extended-release Tablets	5 mg/500 mg, 2.5 mg/1000 mg, and 5 mg/1000 mg		2013-07-31
	Tablets	2.5 mg and 5 mg		2013-07-31

International Patents for Astrazeneca Ab Drugs

Country	Patent Number	Estimated Expiration
New Zealand	593461
Ukraine	77306
Croatia	P20160880
Philippines	12017500778
South Korea	102315836

Supplementary Protection Certificates for Astrazeneca Ab Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1506211	CR 2014 00037	Denmark		PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116
2991656	C20260001	Finland
1506211	C20130006 00074	Estonia		PRODUCT NAME: DAPAGLIFLOZIN;REG NO/DATE: K(2012)8378 12.11.2012
3524680	C20250028	Finland
2498758	2090013-0	Sweden		PRODUCT NAME: A COMBINATION OF METFORMIN HYDROCHLORIDE, SAXAGLIPTIN OR A PHARMACEUTICALLY ACCEPABLE SALT THEREOF, AND DAPAGLIFLOZIN OR PH ARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF; REG. NO/DATE: EU/1/19/1401 20191113

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Astral
• Astrazeneca
• Astrazeneca Ab
• Astrazeneca Lp

AstraZeneca: Market Position, Strengths, and Strategic Insights

Last updated: February 19, 2026

AstraZeneca PLC is a global biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of prescription medicines. Its primary therapeutic areas include oncology, cardiovascular, renal and metabolism, and respiratory and immunology. The company's market position is characterized by a strong presence in key therapeutic segments, a robust pipeline, and strategic acquisitions.

What is AstraZeneca's Current Market Position?

AstraZeneca holds a significant position within the global pharmaceutical market. In 2023, the company reported total revenue of $45.81 billion, a 3.7% increase from $44.39 billion in 2022. This revenue places AstraZeneca among the top ten global pharmaceutical companies by sales.

Revenue Breakdown by Segment (2023):

• Oncology: $25.93 billion
• Cardiovascular, Renal & Metabolism (CVRM): $10.75 billion
• Respiratory & Immunology (R&I): $7.62 billion
• Other: $1.51 billion

The oncology segment is AstraZeneca's largest and fastest-growing division, driven by its blockbuster cancer drugs such as Tagrisso (osimertinib) and Imfinzi (durvalumab). The CVRM and R&I segments also contribute substantially to the company's revenue, with key products like Farxiga (dapagliflozin) and Symbicort (budesonide/formoterol) respectively.

Geographic Revenue Distribution (2023):

• Americas: $12.67 billion
• Europe: $10.71 billion
• Emerging Markets: $11.66 billion
• Japan: $5.75 billion
• Rest of Asia: $5.02 billion

The company demonstrates a balanced geographic footprint, with strong sales in both developed and emerging markets. Emerging markets, in particular, have shown consistent growth, reflecting AstraZeneca's strategic expansion efforts in these regions.

AstraZeneca's market share is substantial within its key therapeutic areas. For example, in the lung cancer market, Tagrisso holds a dominant position as a first-line treatment for EGFR-mutated non-small cell lung cancer. Similarly, Farxiga is a leading SGLT2 inhibitor for type 2 diabetes and heart failure.

What are AstraZeneca's Key Strengths?

AstraZeneca's competitive advantages stem from several core strengths:

1. Robust and Diverse Product Portfolio

AstraZeneca possesses a well-established portfolio of marketed drugs across its core therapeutic areas. These products have achieved significant market penetration and contribute substantially to the company's revenue.

Key Products and Their 2023 Revenues:

• Tagrisso (osimertinib): $9.92 billion (Oncology)
• Imfinzi (durvalumab): $3.47 billion (Oncology)
• Enhertu (trastuzumab deruxtecan): $2.58 billion (Oncology, co-developed with Daiichi Sankyo)
• Farxiga (dapagliflozin): $6.23 billion (CVRM)
• Symbicort (budesonide/formoterol): $2.31 billion (R&I)
• Calquence (acalabrutinib): $2.69 billion (Oncology)

The diversification of revenue across multiple blockbuster products mitigates reliance on any single drug. The strong performance of oncology assets is particularly noteworthy, showcasing the company's successful strategy in this high-growth area.

2. Extensive and Promising R&D Pipeline

AstraZeneca maintains a deep and broad pipeline of investigational medicines. The company invests heavily in research and development, with R&D expenses totaling $10.72 billion in 2023, representing 23.4% of total revenue. This commitment fuels future growth and addresses unmet medical needs.

Pipeline Highlights by Phase (as of early 2024):

• Phase 3: Over 30 molecules
• Phase 2: Over 40 molecules
• Phase 1/Early Phase: Over 100 molecules

The pipeline is weighted towards oncology, with significant investment in novel immunotherapies, targeted therapies, and antibody-drug conjugates. Emerging areas of focus include rare diseases and genetic medicines. The company's commitment to scientific innovation is a critical driver of its long-term sustainability.

3. Strategic Acquisitions and Partnerships

AstraZeneca has a track record of executing strategic mergers, acquisitions, and collaborations to bolster its pipeline and expand its market reach. Recent significant activities include:

• Acquisition of Alexion Pharmaceuticals (2021): This $39 billion acquisition significantly expanded AstraZeneca's presence in rare diseases and immunology, adding blockbuster products like Soliris (eculizumab) and Ultomiris (ravulizumab). Alexion's revenue in 2023 was $6.91 billion.
• Co-development of Enhertu with Daiichi Sankyo: This partnership has yielded a highly successful antibody-drug conjugate for HER2-positive cancers, demonstrating the value of strategic external collaborations.

These moves allow AstraZeneca to rapidly access new technologies, therapeutic modalities, and late-stage assets, accelerating its growth trajectory.

4. Strong Manufacturing and Supply Chain Capabilities

AstraZeneca operates a global network of manufacturing sites, ensuring the reliable production and supply of its medicines. The company has made substantial investments in its manufacturing infrastructure to support current demand and anticipated future growth. This robust supply chain is critical for maintaining market share and meeting patient needs worldwide.

5. Focus on Scientific Leadership and Innovation

The company prioritizes scientific rigor and innovation, evident in its consistent pipeline advancements and its engagement with leading academic institutions and research organizations. This focus enables AstraZeneca to identify and pursue cutting-edge scientific breakthroughs.

What are AstraZeneca's Strategic Imperatives?

AstraZeneca's strategy is designed to drive sustainable growth and enhance shareholder value. Key strategic imperatives include:

1. Continued Leadership in Oncology

Oncology remains a core strategic pillar. AstraZeneca aims to further solidify its leadership through:

• Expansion of Tagrisso's indications: Pursuing new uses for Tagrisso in earlier lines of treatment and different patient populations.
• Advancement of its immuno-oncology portfolio: Leveraging Imfinzi and other investigational agents to improve patient outcomes.
• Development of next-generation therapies: Investing in novel modalities such as bispecific antibodies, cell therapies, and targeted protein degraders.
• Maximizing the potential of Enhertu: Expanding its use in various HER2-expressing solid tumors.

2. Growth in Cardiovascular, Renal, and Metabolism (CVRM)

AstraZeneca seeks to capitalize on the significant unmet needs in CVRM diseases. Key strategies include:

• Expanding Farxiga's application: Exploring its benefits in broader patient populations with cardiovascular and renal disease, beyond its current diabetes indication.
• Developing new treatments for cardiometabolic diseases: Investing in research for novel mechanisms of action to address heart failure, obesity, and chronic kidney disease.

3. Expansion in Respiratory & Immunology (R&I)

The company aims to innovate in R&I by:

• Addressing severe asthma and COPD: Building on the success of Symbicort and developing novel biologics for inflammatory respiratory diseases.
• Growing its immunology franchise: Expanding the use of its existing immunology assets and developing new treatments for autoimmune conditions.

4. Driving Growth in Rare Diseases

Post the Alexion acquisition, rare diseases is a strategic growth engine. AstraZeneca is focused on:

• Leveraging existing rare disease franchises: Maximizing the potential of Soliris and Ultomiris across a wider range of complement-mediated diseases.
• Developing new rare disease therapies: Investing in genetic medicines and other novel approaches to treat rare genetic disorders.

5. Geographic Expansion and Emerging Markets Focus

AstraZeneca continues to prioritize growth in emerging markets. This involves:

• Increasing market access and affordability: Tailoring commercial strategies to meet the specific needs of diverse patient populations.
• Building local infrastructure and partnerships: Strengthening its presence and distribution networks in key emerging economies.

6. Commitment to Sustainability and ESG

AstraZeneca integrates Environmental, Social, and Governance (ESG) principles into its business strategy. This includes:

• Reducing its environmental impact: Setting ambitious targets for carbon neutrality and waste reduction.
• Improving access to healthcare: Working to make medicines more accessible and affordable globally.
• Promoting diversity and inclusion: Fostering an equitable and inclusive workplace.

Key Takeaways

AstraZeneca is a formidable player in the biopharmaceutical industry, characterized by a strong revenue base, a diverse and growing product portfolio, and a robust R&D pipeline. Its strategic focus on oncology, CVRM, R&I, and rare diseases, coupled with disciplined acquisitions and geographic expansion, positions it for continued success. The company's significant investment in R&D underscores its commitment to innovation and addressing significant unmet medical needs.

Frequently Asked Questions

1. What are AstraZeneca's primary therapeutic areas of focus? AstraZeneca's primary therapeutic areas are oncology, cardiovascular, renal and metabolism (CVRM), and respiratory and immunology (R&I). It also has a significant and growing focus on rare diseases, particularly following the acquisition of Alexion Pharmaceuticals.

2. Which of AstraZeneca's products generated the highest revenue in 2023? Tagrisso (osimertinib), an oncology drug, was AstraZeneca's top-selling product in 2023, generating $9.92 billion in revenue.

3. How does AstraZeneca's R&D spending compare to its competitors? AstraZeneca's R&D expenditure in 2023 was $10.72 billion, representing 23.4% of its total revenue. This level of investment is competitive within the pharmaceutical industry, reflecting a commitment to innovation and pipeline development.

4. What was the impact of the Alexion Pharmaceuticals acquisition on AstraZeneca's business? The acquisition of Alexion Pharmaceuticals in 2021 significantly strengthened AstraZeneca's position in rare diseases and immunology. It added blockbuster products like Soliris and Ultomiris to its portfolio and expanded its research capabilities in complement-mediated diseases and genetic disorders.

5. What is AstraZeneca's strategy for growth in emerging markets? AstraZeneca's strategy for emerging markets includes increasing market access and affordability, tailoring commercial approaches to local needs, and building local infrastructure and partnerships to enhance its presence and distribution networks.

Citations

[1] AstraZeneca PLC. (2024). Full Year Results 2023. Retrieved from https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-reports-full-year-and-fourth-quarter-results-2023.html [2] AstraZeneca PLC. (n.d.). Our pipeline. Retrieved from https://www.astrazeneca.com/pipeline.html [3] AstraZeneca PLC. (2023, February 10). AstraZeneca completes acquisition of Alexion Pharmaceuticals. [Press release]. Retrieved from https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-completes-acquisition-of-alexion-pharmaceuticals.html